Clinical Trial Update: Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Itacitinib with high-dose posttransplantation cyclophosphamide in older patients. The study is currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Leukemia
• Multiple Myeloma
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasms
• Plasma Cell Leukemia
• T-cell Prolymphocytic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Itacitinib (itacitinib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Leukemia, Acute, Myelodysplastic Syndromes | Phase 1 | Status: ACTIVE_NOT_RECRUITING